Search

Your search keyword '"Mitten MJ"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Mitten MJ" Remove constraint Author: "Mitten MJ"
47 results on '"Mitten MJ"'

Search Results

2. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.

3. AHA scientific statement. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases.

4. When is disqualification from sports justified? Medical judgment vs patients' rights.

5. BCL-X L -targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.

7. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.

8. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.

9. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X L Inhibitor.

10. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.

11. The Volume of Three-Dimensional Cultures of Cancer Cells InVitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors.

12. A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.

13. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.

14. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology.

15. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

16. Assessment of the 12-lead ECG as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 Years of Age): a scientific statement from the American Heart Association and the American College of Cardiology.

17. Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

18. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

19. Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

20. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

21. Return-to-play decisions: are they the team physician's responsibility?

22. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.

23. Legal issues arising out of blood testing for human growth hormone.

25. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.

26. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.

27. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

28. An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

29. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.

31. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases.

32. Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.

33. Sialylation of lipooligosaccharides promotes biofilm formation by nontypeable Haemophilus influenzae.

34. Criminal consequences of commotio cordis.

35. Efficacies of ABT-773, a new ketolide, against experimental bacterial infections.

36. Legal issues affecting medical clearance to resume play after mild brain injury.

37. Competitive athletes with cardiovascular disease--the case of Nicholas Knapp.

38. Cardiovascular preparticipation screening of competitive athletes: addendum: an addendum to a statement for health professionals from the Sudden Death Committee (Council on Clinical Cardiology) and the Congenital Cardiac Defects Committee (Council on Cardiovascular Disease in the Young), American Heart Association.

39. Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies.

40. Model of Streptococcus pneumoniae meningitis in adult rats.

41. Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association.

43. Legal considerations in treating the injured athlete.

44. HIV-Positive Athletes.

Catalog

Books, media, physical & digital resources